Tag Archives: Exelon

Alzheimer’s Disease Therapies

Current Therapies for Alzheimer’s Disease Because there is currently no cure for Alzheimer’s disease (), the primary goal of treatment remains the relief of cognitive, functional, and behavioral symptoms associated with the disease. Hence, current therapies aim to improve the quality of life for both Alzheimer’s disease patients and the caregivers who often must cope… Read More »

Alzheimer’s Therapy: Acetylcholinesterase Inhibitors

Overview. Acetylcholinesterase inhibitors are the only drugs approved for the treatment of mild to moderate Alzheimer’s disease in the major markets. acetylcholinesterase inhibitors do not cure Alzheimer’s disease but do alleviate the cholinergic deficit observed in Alzheimer’s disease patients. Cognitive symptoms are occasionally improved but most often are only stabilized by the drugs (). Studies… Read More »

 Alzheimer’s Therapy: Rivastigmine

Rivastigmine (Novartis’s Exelon, Sigma Tau/Esteve’s Prometax) () is available in Europe and the United States, where it is indicated for mild to moderate Alzheimer’s disease. Development of rivastigmine in Japan has been discontinued. Novartis is evaluating rivastigmine for the treatment of moderate to severe Alzheimer’s disease in small clinical trials, although it is unclear if… Read More »

Information about Alzheimer’s Disease for Patients and Families

Alzheimer’s disease is the most common and well-known form of degenerative dementia. By definition, dementia is a syndrome, a cluster of symptoms, of impaired memory and cognition. Dementia is a cognitive disorder that impairs an individual’s memory and ability for reasoning, awareness, and judgment. Cognitive impairment in Alzheimer’s disease may involve disturbance of language (aphasia),… Read More »

Schizophrenia: Acetylcholinesterase Inhibitors

Three acetylcholinesterase inhibitors are on the market for the treatment of Alzheimer’s disease: Japan&Japan/Shire/Janssen’s galantamine (Reminyl), Eisai/Pfizer’s donepezil (Aricept), and Novartis’s rivastigmine (Exelon/Prometax). Clinical studies evaluating these agents in the treatment of the cognitive dysfunction and negative symptoms associated with schizophrenia have been performed, but only galantamine appears to be in commercial development for schizophrenia… Read More »

Promoting Well-Being In Persons With Severe Dementia

Involving patients with severe dementia in everyday activities, such as watering the plants or drinking coffee together with other patients and staff, can promote well-being. Zingmark et al showed that such activities could facilitate experiences of ‘at-homeness’, i.e. moments when the patient was interpreted to experience meaningfulness and him/herself as a whole. This was seen… Read More »

Caring Environments For Patients With Severe Dementia

The theory of the person-environment fit conceptualizes behaviour as a product of demands of the environment and the level of personal competence available to meet these demands. The diminishing competence (intellectual, emotional and physical ability) inevitable with the progression of Alzheimer’s disease and related dementias makes it increasingly difficult for the person to interpret the… Read More »

Predicting entry into long-term care

The decision to place a relative in a long-stay facility is a difficult one and brings with it feelings of guilt and grief as well as more positive aspects such as relief from sleeplessness and respite from behavioural disturbance. The decision of when and whether to enter a nursing home can be a planned decision… Read More »

Cholinergic replacement therapy and disease modification

The trials of muscarinic agonists reported thus far are short-term studies concentrating upon symptomatic response. However, it may be that this is the wrong target for the muscarinic receptor agonist because there is some evidence that the most interesting effects of the drugs is to modify disease processes. Amyloid precursor protein () is metabolized in… Read More »